165 related articles for article (PubMed ID: 31454298)
1. The use of 95% CI or 90% CI for drug product development - a controversial issue?
Chow SC; Zheng J
J Biopharm Stat; 2019; 29(5):834-844. PubMed ID: 31454298
[TBL] [Abstract][Full Text] [Related]
2. Frequency estimator for assessing of follow-on biologics.
Lu Y; Zhang ZZ; Chow SC
J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
[TBL] [Abstract][Full Text] [Related]
3. On safety margin for drug interchangeability.
Zheng J; Chow SC; Song F
J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
[TBL] [Abstract][Full Text] [Related]
4. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
5. From bioequivalence to biosimilars: How much do regulators dare?
Weise M
Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
[TBL] [Abstract][Full Text] [Related]
6. From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework.
Karalis VD
Drug Res (Stuttg); 2016 Jan; 66(1):1-6. PubMed ID: 25894088
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the EU Biosimilar Framework: Past and Future.
Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
[TBL] [Abstract][Full Text] [Related]
8. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
9. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
11. Differentiating biosimilarity and comparability in biotherapeutics.
Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
[TBL] [Abstract][Full Text] [Related]
12. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
[TBL] [Abstract][Full Text] [Related]
13. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
14. A consistency approach for evaluation of biosimilar products.
Tsou HH; Chang WJ; Hwang WS; Lai YH
J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
[TBL] [Abstract][Full Text] [Related]
15. The similarity question for biologicals and non-biological complex drugs.
Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS
Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
17. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: An Approach to some Current Worldwide Regulation Frameworks.
Esteban E; Bustos RH; García JC; Jáuregui E
Curr Clin Pharmacol; 2019; 14(1):16-40. PubMed ID: 30360724
[TBL] [Abstract][Full Text] [Related]
20. Comparability and biosimilarity: considerations for the healthcare provider.
Lee JF; Litten JB; Grampp G
Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
